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ABSTRACT
ObjectiveToassessthe effectofweightlossinducedbya
very low energy diet on moderate and severe obstructive
sleep apnoea in obese men.
Design Single centre, two arm, parallel, randomised,
controlled, open label trial. Blocked randomisation
procedure used for treatment allocation.
SettingOutpatientobesityclinicinauniversityhospitalin
Stockholm, Sweden.
Participants 63 obese men (body mass index 30-40, age
30-65 years) with moderate to severe obstructive sleep
apnoea (apnoea-hypopnoea index (AHI) ≥15), treated
with continuous positive airway pressure.
Interventions The intervention group received a liquid
very low energy diet (2.3 MJ/day) for seven weeks to
promote weight loss, followed by two weeks of gradual
introduction of normal food, reaching 6.3 MJ/day at week
9.Thecontrolgroupadheredtotheirusualdietduringthe
nine weeks of follow-up.
Main outcome measure AHI, the major disease severity
index for obstructive sleep apnoea. Data from all
randomised patients were included in an intention to
treat analysis (baseline carried forward for missing data).
ResultsOfthe63eligiblepatients,30wererandomisedto
interventionand33to control.Two patientsinthe control
group were dissatisfied with allocation and immediately
discontinued. All other patients completed the trial. Both
groups had a mean AHI of 37 events/h (SD 15) at
baseline. At week 9, the intervention group’s mean body
weightwas20kg(95%confidenceinterval18to21)lower
than that of the control group, while its mean AHI was 23
events/h (15 to 30) lower. In the intervention group, five
of 30 (17%) were disease free after the energy restricted
diet(AHI<5),with15of30(50%)havingmilddisease(AHI
5-14.9), whereas the AHI of all patients in the control
group except oneremained at 15 or higher.In a subgroup
analysis of the intervention group, baseline AHI
significantlymodifiedtheeffectivenessoftreatment,with
a greater improvement in AHI in patients with severe
obstructive sleep apnoea (AHI >30) at baseline compared
with those with moderate (AHI 15-30) sleep apnoea (AHI
−38 v −12, P<0.001), despite similar weight loss (−19.2 v
−18.2 kg, P=0.55).
Conclusion Treatment with a low energy diet improved
obstructive sleepapnoea in obese men, with the greatest
effect in patients with severe disease. Long term
treatment studies are needed to validate weight loss as a
primary treatment strategy for obstructive sleep apnoea.
Trial registration Current Controlled Trials
ISRCTN70090382.
INTRODUCTION
Obstructive sleep apnoea is common and
underdiagnosed,
1 with estimated prevalences of 24%
in middle aged men and 9% in middle aged
women.
23 Since obesity, old age, heredity, and male
sex are known risk factors for the disorder, prevalence
isexpectedtoriseinthewakeoftheobesityepidemic.
1
Left untreated, obstructive sleep apnoea confers an
increased risk of driving related accidents, cardio-
vascular disease, sudden death during sleep, and all
cause mortality.
124-6
Few treatment options are available for obstructive
sleep apnoea. The most commonly used strategy to
reduce morbidity and mortality, and to improve qual-
ity of life, is continuous positive airway pressure to
facilitate breathing during sleep.
7 Although weight
loss has been advocated as a primary treatment strat-
egy for the condition,
489 little high quality evidence
exists to support this concept. Randomised controlled
trialsareespeciallylacking,promptingquestionsabout
selection bias and residual confounding in available
studies.
10 To the best of our knowledge, only one ran-
domised controlled trial has been published on the
effects of weight loss on obstructive sleep apnoea.
11
However,thestudydidnotincludepatientswithmod-
erate and severe disease, which, unlike the mild form,
are bothassociatedwithincreasedmortality.
56Rando-
mised studies are therefore needed to assess whether
weight losscan improve moderate and severe obstruc-
tive sleep apnoea.
Our aim was, therefore, to assess potential improve-
ment in obstructive sleep apnoea (defined using the
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apnoeas and hypopnoeas per hour of sleep), after
weight loss resulting from a very low energy diet, in
obese men with moderate or severe obstructive sleep
apnoea.
METHODS
Participants
The study was conducted at the Obesity Unit at Karo-
linskaUniversityHospital,KarolinskaInstitute,Stock-
holm, Sweden, between February and April 2009.
Eligible for inclusion were men with moderate to
severe obstructive sleep apnoea (AHI ≥15) treated
with continuous positive airway pressure for a mini-
mum of six months, aged 30-65 years, body mass
index (BMI) 30-40. We excluded those with contrain-
dications for very low energy diets (1.9-3.4 MJ/day)
according to the SCOOP-VLED report,
12 type 1 or
type 2 diabetes, current use of a weight loss drug, pre-
vious bariatric surgery, or recent angina pectoris or
atrial fibrillation.
Allpatientswererecruitedfromapatientdatabaseat
the Aleris FysiologLabsleep clinic in Stockholm, Swe-
den. The database contained date of birth, height,
weight, and data from nocturnal sleep studies in the
past three years. A written invitation and screening
questionnaire were sent to patients who met age, sex,
BMI,andAHIcriteria(fig1).Patientswhodeclaredan
interest in participating and met the inclusion criteria
were asked to attend a compulsory information meet-
ing. Written informed consent was obtained from
those still willing to participate at the end of the infor-
mationmeeting.Patientswerescreenedbyaphysician
to confirm absence of contraindications for a very low
energydietandtoensurethattheywerewellinformed
about the trial aims.
Intervention
The intervention consisted of a weight loss programme
starting with a seven week very low energy diet using a
standard 2.3 MJ/day liquid energy intake protocol
(Cambridge Diet, Cambridge, Northants, UK), fol-
lowed by two weeks of gradual introduction of normal
food to reach 6.3 MJ/day at week 9. At weeks 1, 3, 5, 7,
and9,basicclinical examinationsweredone, including
weight, waist circumference, neck circumference, and
percentage body fat. To confirm dietary compliance,
urinary ketosis was assessed at each visit with test strips
(Keto-Diabur-test 5000, Roche, Switzerland) for detec-
tion of acetoacetic acid (range 5-15 mmol/l). Each visit
included a one hour group session to build group sup-
port and provide motivation. Group sessions were
supervisedbyaresearchnurseandtwostudydietitians.
The patients in the control group were instructed to
adhere to their usual diet. They also attended clinical
examinations at weeks 1, 3, 5, 7, and 9 that were iden-
tical to those of the intervention group, except that
group sessions were not provided. To reduce the like-
lihood of controls dropping out, they were offered the
sameweightlossprogrammeastheinterventiongroup
oncethenineweekfollow-upwascompleted.Afterthe
weight loss programme, all patients were offered a
standard care one year weight maintenance pro-
gramme.
Primary outcome
The primary outcome was AHI, the major disease
severity index for obstructive sleep apnoea. AHI was
assessed at baseline and after the intervention at week
9.Apnoeawasdefinedascompletecessationofairflow
foratleast10secondswhilehypopnoeawasdefinedas
a reduction in airflow for at least 10 seconds.
13 The
severity of obstructive sleep apnoea was defined by
AHI, so that a frequency of five to 14.9 events per
hourisconsideredmild,15-30eventsperhourmoder-
ate, more than 30 events per hour severe, and fewer
than five events per hour, absent.
13 In addition to
AHI, oxygen desaturation episodes of 4% or more
per hour of sleep, the nadir of arterial oxygen satura-
tion, and percentage of supine time were recorded.
AHIandtheothersleepmeasurementswerederived
from two consecutive nocturnal sleep studies in the
home, using a six channel ambulatory polygraphy
equipment(WatchPAT100,ItamarMedicalLtd,Cae-
sarea, Israel). The equipment records peripheral arter-
ial tone, heart rate, oxygen saturation, body position,
November 2008: Invitations sent to patients (n=291)
February 2009: 
Control (n=33)
February 2009:
Intervention (n=30)
Included in analyses (n=33) Included in analyses (n=30)
April 2009:
Completed (n=31)
April 2009:
Completed (n=30)
Non-responders (n=178)
December 2008: Patients interested in participating (n=113)
January and February 2009: Screened by physician (n=72)
February 2009: Randomised (n=63)
Failed inclusion criteria (n=35)
December 2008:
Asked to attend compulsory information meeting (n=78)
January 2009:
Attended meeting and gave written informed consent (n=72)
Absent from meeting (n=6)
Withdrawn consent (n=4)
Type 2 diabetes mellitus (n=1)
AHI <15 (n=1)
BMI <30 (n=1)
BMI >40 (n=1)
Hypertension (n=1)
Dissatisfied with
allocation (n=2)
Fig 1 | Flow of participants.
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respiratory disturbance index, AHI, and sleep-wake
state. AHI measurement data were received automati-
cally from the built-in software by a programmed
mathematical algorithm. The algorithm was based on
attenuation of the peripheral arterial tone in combina-
tion with heart rate and oxygen saturation excluding
events during perceived wake periods.
14 To decrease
the effect of random variations, the average from the
two consecutive nights was used for all the sleep mea-
surements.
Patients were carefully instructed to refrain from
using their continuous positive airway pressure device
forthetwonightsbeforeandduringthenocturnalsleep
studies. To avoid possible artefacts interfering with the
automatic interpretation, such as arrhythmias, periodic
limb movement, and related autonomic arousals, all
sleep data were manually reviewed by a physician,
who noted no major disturbances. Sleep studies with
an estimated sleep time of less than three hours were
excluded.Atbaseline,sixpatientsdidnotrecordduring
oneofthetwonights(threeintervention,threecontrol),
and seven patients did not record one of the two nights
at follow-up (four intervention, three control).
Secondary outcomes
Fat loss was assessed with anthropometry and body
composition changes from baseline at weeks 1, 3, 5,
7, and 9. Percentage body fat and body weight were
measured with the Tanita BC-418MA body fat analy-
ser (Tanita Corporation of America, Arlington
Heights, IL, USA), which has been validated for mea-
suringchangeinadiposity.
15Standingheightwasmea-
sured to the nearest centimetre with a wall mounted
stadiometer. Waist circumference was measured in
duplicate between the iliac crest and the lower rib
cage, with patients standing in underwear. Neck cir-
cumference was measured in duplicate at the level of
the superior border of the cricothyroid membrane.
Daytime sleepiness was assessed with the Epworth
sleepinessscale,
16aneightitemselfadministeredques-
tionnaire. The patients rated on a four point scale (0-3)
the chances of dozing off or falling asleep in eight dif-
ferent situations. When responses are added they pro-
vide a daytime sleepiness score. A score of 0-9 is
considered normal, whereas a score of 10-24 indicates
a possibility of excessive daytime sleepiness.
Safety
Adverse events from the very low energy diet were
notedbythestudynurseateachvisit,andsubsequently
classified by the study physician for potential causality
(unlikely, possibly, or likely). The most common
adverse events from a very low energy diet are dry
mouth, diarrhoea, constipation, headache, nausea or
vomiting,dizziness,cramps,fatigue,hunger,visualdis-
turbance, feeling cold, hair loss, gallstones, and gout,
all of which are considered transient.
12
Randomisation
Sixtythreepatientsmetthestudyinclusioncriteriaafter
the physician screening, and were subsequently ran-
domly assigned to intervention or control groups in a
1:1 ratio. A member of the research team who was not
involvedintherecruitmentprocess,wasgivenalistcon-
taining only study identification number, AHI, and
BMI. Each identification number was then put into
one of four categories of AHI and BMI (low AHI and
low BMI; low AHI and high BMI; high AHI and low
BMI;orhighAHIandhighBMI,usingscreeningmed-
ian values as cut offs). Each category contained a com-
puter generated random sequence of 18 As
(intervention)and18Bs(control).Oncethe studyiden-
tification numbers were in their correct category, they
were sequentially allocated to intervention or control.
The randomisation lists were kept in a locked room,
with no access for recruitment staff. When all patients
were randomised, a list of study identification numbers
and allocation was sent to study administrators who
informed the patients of their allocation. In view of the
use of a liquid very low energy diet, blinding of staff or
participants was not considered feasible.
Sample size
The sample size calculation was based on 80% power
withanαlevelof5%todetectadifferenceinAHIof15
eventsanhourbetweengroupsusinga twosidedinde-
pendentStudent’sttest.Weassumedastandarddevia-
tion of the within group AHI difference of 18 events
per hour based on two previous studies.
1718 This
resulted in a required sample size of 24 patients in
each group. To avoid loss of power due to dropout,
we increased the final recruitment goal by 25%, result-
inginarecruitmenttargetof30patientsineachgroup.
Statistical analysis
Mean values and standard deviations were used to
describe the baseline characteristics and within group
changes in the two groups.
Changeswerecalculatedbysubtractingthebaseline
measurement from the nine week follow-up measure-
ment. The mean difference in change between groups
was used as main treatment effect along with 95% con-
fidence intervals. Changes between groups from base-
linetoweek9wereanalysedwithindependentsamples
t test.
EffectmodificationbybaselineAHIwasinvestigated
by fitting a linear regression model with AHI at week 9
as the outcome variable, and baseline AHI, treatment
group(interventionorcontrol),andaninteractionterm
(baseline AHI×treatment group) as predictors.
Adiposity measures were also analysed with
repeated measures ANOVA with group×time inter-
action.
All analyses were done on an intention to treat basis
with baseline carried forward for missing data. A per
protocolanalysiswasalsodoneasasensitivityanalysis.
Of 378 planned examinations in dietary compliance
and adiposity measures, we were able to do 360
RESEARCH
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control group. All data were analysed with SPSS (ver-
sion 17.0, Chicago, IL) and Stata (version 10, College
Station, TX, USA).
RESULTS
Sixty three men were randomised to intervention
(n=30) or control (n=33). All patients completed the
trial apart from two control patients who were dissatis-
fied with allocation and immediately discontinued the
trial (fig 1).
Table 1 shows the characteristics of the two groups.
Forbothgroupscombined,meanagewas49years(SD
7.3, range 33-61), mean AHI 37 events/h (15, 15-77),
mean weight 112.5 kg (14.2, 86.9-141.9), and mean
waist circumference 120 cm (9, 101-139). Forty four
per cent of the patients had moderate obstructive
sleep apnoea (AHI 15-30) and the remaining 56%
had severe obstructive sleep apnoea (AHI >30). Sixty
per cent were class I obese (BMI 30.0-34.9) and 40%
were class II obese (BMI ≥35).
Compliance
Duringthesevenweeksoftheverylowenergydiet,all
patients in the intervention group complied with the
diet, as assessed by urinary ketosis (5-15 mmol/l at
eachvisit).Ketosiswasnotpresentinanyofthecontrol
patients during the nine weeks.
Adiposity change
At week 9, all four adiposity measures differed signifi-
cantly between groups (figure 2, all P<0.001). In the
intervention group, the mean change in weight was
−18.7 kg (SD 4.1; range −26.7 to −10.6) and mean
change in BMI was −5.7 (1.1; −8.2 to −3.4), compared
with 1.1 kg (1.9; −2 to 6.2) and 0.3 (0.6; −0.6 to 1.9) in
the control group. Twenty two of 30 (73%)
intervention patients were non-obese (BMI<30) at
week 9, whereas all control patients remained obese.
Primary outcome
Atweek9,meanAHIintheinterventiongroupwas12
(SD 7, range 1-30) compared with 35 (14, 14-75) in the
control group (table 2). In the intervention group, a
dose-response relation existed between weight loss
Table 1 |Baseline characteristics
Intervention (n=30) Control (n=33)
Age (years) 47.5 (7.5) 49.9 (7.1)
Weight (kg) 113.4 (14.8) 111.7 (13.7)
Height (m) 1.82 (0.1) 1.79 (0.1)
Body mass index 34.4 (2.9) 34.8 (2.9)
Waist circumference (cm) 120.1 (9.0) 120.5 (8.6)
Neck circumference (cm) 45.1 (2.1) 44.2 (1.8)
Body fat (%) 30.1 (3.7) 31.7 (3.2)
Apnoea-hypopnoea index (events/h) 37 (17) 37 (14)
15-30 (moderate) 50% (15) 39% (13)
>30 (severe) 50% (15) 61% (20)
Apnoea-hypopnoea index (events/h, supine) 49 (22) 48 (20)
Percentage supine time 52 (26) 48 (21)
Oxygen desaturation episodes ≥4%/h of sleep 26 (15) 25 (14)
Oxygendesaturationepisodes≥4%/hofsleep(supine) 37 (23) 35 (20)
Nadir of arterial oxygen saturation (%) 82 (6) 82 (5)
Epworth sleepiness scale 9 (5) 7 (5)
Data are mean (SD).
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Fig 2 | Changes from baseline in body weight (A), waist
circumference (B), neck circumference (C), and percentage
body fat (D). Data are mean difference between groups (95%
confidence interval). P<0.001 for intervention v control group
for all comparisons.
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(r=0.4, P=0.04, appendix 1).
Using AHI cut offs for mild, moderate, and severe
obstructive sleep apnoea, 12 of 30 (40%) in the inter-
vention group improved by two categories of AHI, 14
of 30 (47%) improved by one category, and four of 30
(13%) remained in the same category. In the control
grouponeof33(3%)improvedbytwoAHIcategories,
three of 33 (9%) improved by one AHI category, 24 of
33 remained static (73%), and five of 33 worsened to a
higher AHI category (15%) (fig 3).
Baseline AHI significantly modified the treatment
effect (P<0.001, figure 4 and appendix 2) in the inter-
ventiongroup.Intheinterventiongroup,thechangein
AHIinpatientswithsevereobstructivesleepapnoeaat
baseline was −38 and −12 for those with moderate dis-
ease (P<0.001, control-group adjusted change of −33
for those with moderate disease and −14 for severe).
This meant that the mean AHI at week 9 was similar
for patients with moderate obstructive sleep apnoea at
baseline as for those with severe disease at baseline
(AHI 11 v 13, P=0.45).
The modification of treatment effect by baseline
AHI was not explained by differences between
patients with moderate compared with severe sleep
apnoea in any of the adiposity measurements at base-
line, age, or weight loss achieved at week 9 (−19.2 v
−18.2kg,P=0.55)between.Furthermore,AHIatbase-
line did not correlate with any of the adiposity mea-
sures.
Secondary sleep outcomes
ApartfromAHI,theinterventiongroupalsoimproved
in other sleep variables compared with the control
group (table 2). In terms of self reported outcomes,
reductions in daytime sleepiness score at week 9 were
greater in the intervention group than in the control
group (P<0.001).
Safety
Eight adverse events were classified by the study physi-
cian as being likely to be causally linked with the very
lowenergydiet.Thesewereconstipation(n=3),elevated
alanineaminotransferaseconcentrations(n=2),dizziness
(n=1), gout (n=1), and dry lips (n=1). All adverse events
were transient and not presentat week9. Nopatient dis-
continued treatment due to adverse events and no
adverse events occurred in the control group.
Sensitivity analysis
Use of a per protocol analysis, rather than intention to
treat analysis with baseline carried forward, did not
materially change our findings for any of the reported
outcomes (appendix 3).
Table 2 |Changes in obstructive sleep apnoea measures between baseline and week 9
Intervention
(n=30)
Control
(n=33)
Mean
difference P
AHI (events/h) −25 (17) −2( 1 1 ) −23 (−30 to −15) <0.001
AHI (events/h; supine) −27 (25) −1( 1 2 ) −27 (−36 to −17) <0.001
Percentage supine time −5 (25) 2 (22) −7( −5 to 18) 0.28
Oxygen desaturation episodes ≥4%/h of sleep −19 (14) −1( 9 ) −18 (−24 to −12) <0.001
Oxygen desaturation episodes ≥4%/h of sleep (supine) −23 (23) −0( 1 0 ) −23 (−32 to −14) <0.001
Nadir of arterial oxygen saturation (%) 5 (6) 0 (5) 5 (2 to 7) 0.002
Epworth sleepiness scale −3( 5 ) 1( 3 ) −4( −6t o−2) <0.001
Data are mean (SD) for within group comparisons, and mean (95% confidence interval) for between group comparisons. P values from independent
samples t tests. AHI=apnoea-hypopnoea index.
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Fig 3 | Obstructive sleep apnoea at week 9. Proportions of
patients defined as having no (cured), mild, moderate, or
severe obstructive sleep apnoea at week 9 (A). Proportions of
patients who improved, maintained, or worsened their
obstructive sleep apnoea status after 9 weeks (B). Error bars
are 95% confidence intervals. Definitions: Cured defined as
AHI <5 events/h, mild 5-14.9 events/h, moderate AHI 15-30
events/h, severe >30 events/h. Improvement defined as shift
in severity of obstructive sleep apnoea—that is, moderate to
cured or mild; or severe to cured, moderate or mild.
Worsening defined as opposite direction of improvement. No
change defined as remaining within the same category of
severity of obstructive sleep apnoea.
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Treatmentwithalowenergydietresultedinaclinically
meaningful reduction of moderate to severe obstruc-
tive sleep apnoea in obese men. AHI was reduced by
67% in the intervention group compared with no
change in the control group. Of the patients in the
intervention group, those with severe sleep apnoea at
baseline had significantly greater reductions in AHI
than did those starting with moderate sleep apnoea.
Seventeen per cent of the intervention group patients
were classified as free of obstructive sleep apnoea at
week 9. Daytime sleepiness was also reduced in the
intervention group. An added benefit of the treatment
wasthat73%ofpatientsintheinterventiongroupwere
no longer classified as obese, whereas all control
patients remained obese.
Strengths and weaknesses
The strengths of this study include the randomised
controlled design, which implies a low probability of
selection bias and residual confounding.Furthermore,
thestudyhadalowdropoutrate,withfewmissingdata,
ample statistical power, duplicated sleep studies, and
investigation of a patient group with increased risk of
mortality. Additionally, the low cost, low energy diet
treatmentprogrammeusedcouldpotentiallybeimple-
mented in primary care. The main limitation is the
short study duration, which means that the long term
effect of weight loss by a very low energy diet on mod-
erate to severe obstructive sleep apnoea remains
uncertain. Although the study supports a beneficial
role of weight loss on obstructive sleep apnoea, the
duration was not sufficient to constitute validation of
treatment. Indeed, since weight regain is common
after weight loss,
19 weight loss trials purporting to be
treatment studies of any obesity comorbidity should
have a minimum duration of a year.
In terms of data quality, the gold standard method
for diagnosing obstructive sleep apnoea is poly-
somnography. However, high costs, limited access to
sleep laboratories, and the increasing number of
patients with obstructive sleep apnoea, have led to
thedevelopmentofmoreaccessibleandcheapermeth-
ods, such as the portable monitors used in this study.
Validation studies have shown that the manually por-
table devices based on peripheral arterial tone records
have high sensitivity and specificity to identify patho-
logical respiratory disturbances and estimate sleep
time compared with polysomnography.
1420
Previous research
Although obesity has been identified as a modifiable
risk factor for obstructive sleep apnoea,
1 few studies
exist that investigate the effect of diet induced weight
loss to treat the disease.
10 Indeed, we could only iden-
tify one randomised intervention study that assessed
the effect of weight loss on obstructive sleep apnoea.
11
The authors in that study noted a 40% reduction in
AHI from a weight loss of 10.7 kg after a year in
patients with mild disease. Uncontrolled studies have
also noted improvements in obstructive sleep apnoea
(defined by oxygen desaturation episodes, ≥4% per
hour of sleep) from weight loss following a very low
energy diet, with weight loss ranging between 9-21 kg
and improvements in oxygen desaturation ranging
from 12 to 54 episodes per hour.
21-25 However, these
studies had small sample sizes (eight to 31 patients),
and their designs were susceptible to bias and con-
founding (no control group and no randomisation).
Despite these limitations, these studies indicate treat-
ment effects of similar size to that seen in the current
study and the previously published randomised con-
trolled trial on mild obstructive sleep apnoea.
11 Addi-
tionally, prospective cohort studies have shown that
weight gain is associated with increased risk of sleep
apnoea, and conversely that weight loss is associated
with improvement in obstructive sleep apnoea.
26-28
Future research priorities include intervention stu-
dies with longer duration so that the long term effec-
tiveness of weight loss programmes can be clarified.
Longtermweightlosswillalsohaveafavourableeffect
onotherobesitycomorbidities,suchastype2diabetes
and cardiovascular disease, which often coexist with
obstructive sleep apnoea. Indeed, a prevalence study
showedthat87%ofobesepatientswithtype2diabetes
had at least mild sleep apnoea.
29
Another area that needs further study is whether
amount of weight loss is associated with sleep apnoea
improvement. In this trial, the association between
weight loss and AHI improvement was significant,
although of modest strength (r=0.4). This relation sug-
gests that factors other than weight loss are also
involved in the improvement of sleep apnoea.
Clinical implications
Arguments for large scale implementation of weight
loss programmes by very low energy diet in the
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Fig 4 |Association between AHI at baseline and follow-up for
intervention group (thick blue line) and control group (broken
red line). Thin black line represents no change in AHI from
baseline
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tive safety and effectiveness of a very low energy diet
and the low cost compared with bariatric surgery.Bar-
iatric surgery, currently the most effective method for
treatingobesity,resultsinweightlossofabout25-30kg
after 10 years.
30 Evidence is emerging that bariatric
surgery is effective in treating obstructive sleep
apnoea.
1831-33 However, since the prevalence of
obstructive sleep apnoea is expected to rise in the
wake of the obesity epidemic,
1 provision of bariatric
surgerytoallpatientswiththisproblem isnot realistic.
Non-surgical treatment schemes, preferably of lower
cost than bariatric surgery and with proved effective-
ness,arethereforeneeded.Themainargumentagainst
a weight loss programme using a very low energy diet
is the uncertainty regarding weight loss maintenance.
However, a systematic review of randomised weight
loss trials with a minimum follow-up of a year showed
that very low energy diets resulted in a greater (10%)
weight reduction from baseline weight after a year,
compared with drug treatment (8%).
19 One promising
approachtoimproveweightlossmaintenanceistouse
anti-obesitydrugsaftertheactiveweightlossphase.
34-36
Whether such a treatment scheme would be effective
in promoting long term improvements in obstructive
sleep apnoea needs clarification.
In conclusion, the findings of this randomised trial
show that weight loss induced by a very low energy diet
improvedmoderatetosevereobstructivesleepapnoeain
obesemen.Patientswithseveresleepapnoeahadgreater
improvements than those with moderate disease.
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